Two Sigma Advisers’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.09M | Sell |
764,300
-94,100
| -11% | -$134K | ﹤0.01% | 1398 |
|
|
2025
Q1 | $1.31M | Sell |
858,400
-119,000
| -12% | -$182K | ﹤0.01% | 1340 |
|
|
2024
Q4 | $2.42M | Sell |
977,400
-324,100
| -25% | -$804K | 0.01% | 1030 |
|
|
2024
Q3 | $1.5M | Sell |
1,301,500
-135,400
| -9% | -$156K | ﹤0.01% | 1228 |
|
|
2024
Q2 | $1.58M | Sell |
1,436,900
-14,200
| -1% | -$15.6K | ﹤0.01% | 1319 |
|
|
2024
Q1 | $1.8M | Buy |
1,451,100
+30,100
| +2% | +$37.3K | ﹤0.01% | 1286 |
|
|
2023
Q4 | $1.49M | Buy |
1,421,000
+1,275,000
| +873% | +$1.34M | ﹤0.01% | 1440 |
|
|
2023
Q3 | $1M | Buy |
146,000
+121,700
| +501% | +$834K | ﹤0.01% | 1519 |
|
|
2023
Q2 | $252K | Sell |
24,300
-16,200
| -40% | -$168K | ﹤0.01% | 2035 |
|
|
2023
Q1 | $328K | Buy |
+40,500
| New | +$328K | ﹤0.01% | 2107 |
|
|
2022
Q1 | – | Sell |
-13,300
| Closed | -$193K | – | 2715 |
|
|
2021
Q4 | $193K | Sell |
13,300
-3,100
| -19% | -$45K | ﹤0.01% | 2296 |
|
|
2021
Q3 | $295K | Sell |
16,400
-56,800
| -78% | -$1.02M | ﹤0.01% | 2125 |
|
|
2021
Q2 | $1.29M | Buy |
73,200
+12,900
| +21% | +$226K | ﹤0.01% | 1519 |
|
|
2021
Q1 | $1.52M | Buy |
60,300
+13,100
| +28% | +$330K | ﹤0.01% | 1409 |
|
|
2020
Q4 | $305K | Buy |
47,200
+24,000
| +103% | +$155K | ﹤0.01% | 2038 |
|
|
2020
Q3 | $60K | Sell |
23,200
-2,700
| -10% | -$6.98K | ﹤0.01% | 2311 |
|
|
2020
Q2 | $42K | Sell |
25,900
-8,800
| -25% | -$14.3K | ﹤0.01% | 2436 |
|
|
2020
Q1 | $36K | Sell |
34,700
-23,200
| -40% | -$24.1K | ﹤0.01% | 2393 |
|
|
2019
Q4 | $109K | Sell |
57,900
-97,100
| -63% | -$183K | ﹤0.01% | 2245 |
|
|
2019
Q3 | $167K | Buy |
+155,000
| New | +$167K | ﹤0.01% | 2072 |
|